An exploratory single-donor ex vivo study found that the A2-B-H MRSA peptide combination had the strongest integrated ...

Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early or mild Alzheimer’s disease, with topline data expected in the ...

A 20-year-old woman with large bilateral ovarian masses was diagnosed with B-lymphoblastic leukemia after lymph-node and bone ...

From October 10 to October 16, we covered 6 items: 4 in oncology and 2 in neurology. The list features drugs with novel ...

This article selects and organizes clinical trials that should be monitored for competitive trends from among those with 'new registrations' or 'status changes' in ClinicalTrials.gov (CTgov) during ...

T-Cell Malignancies Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight. The T-Cell Malignancies clinical trial analysis ...

Tiziana Life Sciences Ltd. announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early/mild ...

Tiziana Life Sciences, Ltd. ( TLSA) announced that the last patients has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with ...

Wuhan YZY Biopharma Co., Ltd. announced that the first patient had been dosed in the Phase I clinical study of Y225, an emicizumab biosimilar under development by the Company in the PRC. This Phase I ...

Interleukins are cytokines produced and secreted mainly by CD3+ and CD4+ T lymphocytes. Interleukins promote development and differentiation of natural killer cells, T and B lymphocytes and ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead ...